A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms LEAP-002
- Sponsors Merck Sharp & Dohme
- 04 Jun 2019 Trial densig presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jan 2019 Status changed from not yet recruiting to recruiting.
- 29 Oct 2018 New trial record